Mental health nursing is not for sale: Rethinking nursing's relationship with the pharmaceutical industry

Journal of Psychiatric and Mental Health Nursing

Volumn 17, Issue 2, 2010, Pages 172-177

  Lakeman, R ^a,b  

^a JAMES COOK UNIVERSITY   (Australia)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; IRELAND; MEDICAL ETHICS; MENTAL DISEASE; NOTE; NURSING; OFF LABEL DRUG USE; PSYCHIATRIC NURSING;

CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; ETHICS, NURSING; HUMANS; IRELAND; MENTAL DISORDERS; OFF-LABEL USE; PSYCHIATRIC NURSING; PSYCHOTROPIC DRUGS;

EID: 77949283144     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/j.1365-2850.2009.01516.x     Document Type: Note

References (40)

1. Partnerships in wellbeing flyer. 2008, http://www.acmhn.org/Lilly_Partnerships_Flyer.pdf, ACMHN, Available at: (accessed 4 May 2008
2. Ashmore R, Carver N. The pharmaceutical industry and mental health nursing. British Journal of Nursing 2001, 10:1396-1402.
3. Ashmore R, Carver N, Banks D. Mental health nursing students' relationships with the pharmaceutical industry. Nurse Education Today 2007, 27:551-560.
4. Barker P. The Philosophy and Practice of Psychiatric Nursing 1999, Churchill Livingstone, Edinburgh
5. Berenson A. Finance: Eli Lilly settles a suit on drug's side effects. The International Herald Tribune 2008, 14. 17 March 2008
6. Bjorhus J. Minnesota to get $4 million in Bristol-Myers Squibb settlement [Electronic Version]: Pioneer Press. 2008, http://www.twincities.com/ci_9961621, Available at: (accessed 29 July 2008
7. Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine 2005, 352:1112-1120.
8. Bracken P, Thomas P. Authors' response. invited commentary on . . . Beyond consultation. Psychiatric Bulletin 2009, 33:245-246.
9. Alkermes reports financial results for fiscal 2008 and provides financial expectations for fiscal 2009 [Electronic Version]. 2008, http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_22/ai_n25452217, Business Wire, Available at: (accessed 30 July 2008
10. Carver N, Ashmore R. Anything to declare? Competing interests in mental health nursing journals. Journal of Psychiatric and Mental Health Nursing 2004, 11:620-622.
11. Civaner M, Sarikaya O, Alici SU. Exposing nursing students to the marketing methods of pharmaceutical companies. Nursing Ethics 2008, 15:396-410.
12. Fugh-Berman A, Melnick D. Off-label promotion, on-target sales. PLoS Medicine 2008, 5:1432-1435.
13. Gray R, Robson D. Concordance Skills: A Manual for Mental Health Workers 2006, Jansees-Cilag Pty, Australia
14. Green S. Ethics and the pharmaceutical industry. Australasian Psychiatry 2008, 16:158-165.
15. Hemingway S. Mental health nursing and the pharmaceutical industry. Mental Health Nursing and the Pharmaceutical Industry 2003, 7:22-29.
16. Hodge K, Jespersen S. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. International Journal of Mental Health Nursing 2008, 17:2-8.
17. Hopkins Tanne J. Antipsychotic use among US young people has risen sixfold. British Medical Journal 2006, 332:1407.
18. Josefson D. Marketing of antipsychotic drugs attacked. British Medical Journal 1998, 316:645.
19. Jutel A, Menkes DB. Soft targets: nurses and the pharmaceutical industry. PLoS Medicine 2008, 5:193-198.
20. Kirsch I, Deacon BJ, Huedo-Medina TB. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Medicine 2008, 5:e45. doi:10.1371/journal.pmed.0050045
21. Komesaroff I, Kerridge H. Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry. Medical Journal of Australia 2002, 176:118-121.
22. Lakeman R, Cutcliffe J. Misplaced epistemological certainty and pharmaco-centrism in mental health nursing. Journal of Psychiatric and Mental Health Nursing 2009, 16:199-205.
23. Press release: Lilly reports solid first-quarter results. 2008, http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=916306&TICK=LLY&STORY=/www/story/04-21-2008/0004796315&EDATE=Apr+21,+2008, Lilly, Available at: (accessed 25 July 2008
24. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. British Medical Journal 2006, 331:155-157.
25. CG23 Depression: NICE guideline (amended). 2007, http://guidance.nice.org.uk/CG23/NiceGuidance/pdf/English, National Institute for Health and Clinical Excellence, Available at: (accessed 9 July 2009
26. PSU national prescribing report 2008-9, quarter ending March 2009, England. 2009, http://www.ic.nhs.uk/webfiles/Services/PSU/NatPresReport%20Q4%200809.pdf, NHS Information Centre, Available at: (accessed 16 September 2009
27. Pendlebury J, Bushe CJ, Wildgust HJ. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatrica Scandinavica 2007, 115:286-294.
28. Peplau HE. Interpersonal Relations in Nursing 1952, Putnam, New York
29. Pierce D, Gunn J. Using problem solving therapy in general practice. Australian Family Physician 2007, 36:230-233.
30. Rizo C. Squibb settles with states for $403 million. 2008, http://www.legalnewsline.com/news/214168-squibb-settles-with-states-for-403-million, Available at: (accessed 15 September 2009
31. Rosack J. Lilly to pay out millions to settle lawsuits over zyprexa. Psychiatric News 2007, 42:1.
32. Rothman DJ, McDonald WJ, Berkowitz CD. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009, 301:1367-1372.
33. Rubak S, Sandbæk A, Lauritzen T. Motivational interviewing: a systematic review and meta-analysis. British Journal of General Practice 2005, 55:305-312.
34. Smith S, Yeomans D, Bushe CJP. A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. European Psychiatry 2007, 22:413-418.
35. Spicer J. Clinical ethics and the commercial pressures on prescribing. Nurse Prescribing 2006, 4:373-375.
36. Steinbrook R. Physician-industry relations - will fewer gifts make a difference? New England Journal of Medicine 2009a, 360:557-559.
37. Steinbrook R. Controlling conflict of interest - proposals from the institute of medicine. New England Journal of Medicine 2009b, 360:2160-2163.
38. Turner EH, Matthews AM, Linardatos E. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008, 358:252-260.
39. Whitfield G, Williams C. The evidence base for cognitive-behavioural therapy in depression: delivery in busy clinical settings. Advances in Psychiatric Treatment 2003, 9:21-30.
40. Zmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. British Medical Journal 2009, 338:b217.